CT-101
Sickle Cell Disease
Pre-clinicalActive - Lead candidate nominated
Key Facts
Indication
Sickle Cell Disease
Phase
Pre-clinical
Status
Active - Lead candidate nominated
Company
About Cetya Therapeutics
Founded in 2012 and based in Fort Collins, Colorado, Cetya Therapeutics is developing isoform-selective histone deacetylase inhibitors (HDACi) derived from largazole, a natural product. The company has nominated its lead candidate, CT-101, for the treatment of sickle cell disease, a significant unmet medical need. Cetya has strengthened its leadership with key board appointments and secured intellectual property through a process patent for its novel synthetic route, positioning itself to advance its pipeline.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Research |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| Endari (L-glutamine oral powder) | Emmaus Life Sciences | Approved |
| Undisclosed | Biossil | Phase 2/3 |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Digital Model for Sickle Cell Disease | Koneksa Health | Development/Validation |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| CLY-124 | Cellarity | Phase 1 |
| AB1 | AkiraBio | Pre-clinical |
| Oral Decitabine/Tetrahydrouridine | Novo Nordisk | Phase 2 |